# Willem J. Remme

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/willem-j-remme/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,536 |
| Field | Heart Failure Treatment and Management |
| h-index | 48 |
| i10-index | 109 |
| Last Known Institution | AstraZeneca (United Kingdom) |
| OpenAlex ID | https://openalex.org/A5035807664 |
| Works | 230 |

## Researcher papers

- [The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure](https://scholariq.org/papers/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe/)
- [Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction](https://scholariq.org/papers/eplerenone-a-selective-aldosterone-blocker-in-patients-with-left-ventricular/)
- [The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure](https://scholariq.org/papers/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe-2/)
- [Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-treatment-of-chronic-heart-failure-executive/)
- [Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial](https://scholariq.org/papers/comparison-of-carvedilol-and-metoprolol-on-clinical-outcomes-in-patients-with/)
- [Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival](https://scholariq.org/papers/early-thrombolysis-in-acute-myocardial-infarction-limitation-of-infarct-size-and/)
- [Comprehensive Guidelines for the Diagnosis and Treatment of Chronic Heart Failure Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology](https://scholariq.org/papers/comprehensive-guidelines-for-the-diagnosis-and-treatment-of-chronic-heart/)
- [IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION](https://scholariq.org/papers/improved-survival-after-early-thrombolysis-in-acute-myocardial-infarction/)
- [Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure](https://scholariq.org/papers/hemodynamic-and-neurohumoral-effects-of-continuous-infusion-of-levosimendan-in/)
- [The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction](https://scholariq.org/papers/the-ephesus-trial-eplerenone-in-patients-with-heart-failure-due-to-systolic/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiac electrophysiology and arrhythmias](https://scholariq.org/topics/cardiac-electrophysiology-and-arrhythmias/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)

## Researcher university

- [AstraZeneca (United Kingdom)](https://scholariq.org/institutions/astrazeneca-united-kingdom/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.